Experts in Electronic Submissions in ECTD Format
TruSubmit LLC is a premier provider of end-to-end eSubmissions solutions for the biotechnology,
pharmaceutical, and medical device industries worldwide. With over 15 years of experience working
with US-based and international clients to compile and submit paper and electronic drug
applications to the FDA and other regulatory agencies globally, we are your partner in supporting
all of your electronic regulatory submissions requirements.
As a full service provider, we offer complete eCTD
services including compilation, validation, and publication of
submissions in eCTD format for FDA, Health Canada, and European agencies. We also provide comprehensive
training seminars for companies just getting started with electronic submissions to those with
existing levels of expertise. We can even assist you with bringing publishing capabilities
in-house. No matter where you are in the drug development process, we can tailor
to meet your needs.
There are many benefits to electronic submissions, including:
- FDA and other regulatory agencies prefer the eCTD format and are strongly encouraging sponsors to move to this format because it’s easier to navigate and review than paper format
- Providing submissions electronically to FDA/EMA can expedite their review and accelerate
- eSubmissions improve overall communication with the FDA/EMA and allow for quicker, more streamlined communications
We are currently recruiting E-Submissions Publishers for immediate hire!
Work involves computer and word processing of scientific and regulatory documents.
Associate's degree (or higher) is preferred. Flexible hours and remote work are possible for
full-time and part-time positions, upon completion of training.
Signing bonus may be offered.
Please send your resume and cover letter to info@TruSubmit.com.
In February 2020, the FDA finalized its guidance on providing regulatory submissions in eCTD format
(more info here).
The guidance also specifies which submission types are exempt from eCTD requirements or may qualify for
a long-term waiver, such as Type III drug master files. For those submission types,
FDA issued a draft guidance on providing submissions in alternate electronic format (March 2020,
more info here).
For more information about the eCTD v4.0,
see the FDA's draft Technical Conformance Guide and Module 1 Implementation Package
and the current ICH implementation package